Reduction of Insulin Requirement After Starting Treatment With Sacubitril/Valsartan in a Patient with Diabetes Treated With Continuous Subcutaneous Insulin Infusion (CSII): A case report

Podobne knjige/članki

• Continuous subcutaneous insulin infusion (CSII) does not prevent progression of proliferative and preproliferative retinopathy.
  od: Lawson, P M, et al.
  Izdano: (1982)
• Changes in Insulin Requirements From the Onset of Continuous Subcutaneous Insulin Infusion (CSII) Until Optimization of Glycemic Control
  od: Chico, Ana, et al.
  Izdano: (2014)
• A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
  od: King, Allen B., et al.
  Izdano: (2016)
• Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes
  od: Lyu, Fu-ping, et al.
  Izdano: (2020)
• Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy
  od: Li, Feng-fei, et al.
  Izdano: (2018)